Enhance human healthcare.
Develop and supply best-in-class, affordable products for diagnosis and treatment.
Science, data, and determination against treatable infection.
Delphine Diagnostics is a New Jersey-based healthcare startup developing rapid molecular diagnostics and AI/ML-enabled clinical decision support to help clinicians identify sepsis risk earlier and move patients toward effective treatment faster.
A mission-driven diagnostics company built around time-critical care.
Sepsis is a medical emergency where every hour matters. Yet clinicians often face overlapping symptoms, slow culture workflows, and limited information when critical treatment decisions must be made.
Delphine brings together biomedical science, molecular biology, machine learning, clinical insight, data analytics, operations, and commercialization. Our goal is to reduce diagnostic uncertainty by uniting rapid pathogen and resistance-marker identification with earlier, explainable risk prediction.
Speed effective diagnosis and treatment.
Deliver reliable diagnostic products and supplemental data insights for patients with infectious diseases, guided by affordability, quality, and real-world clinical need.
Connect trusted testing with intelligent software.
Pair certified molecular testing kits with AI/ML applications that strengthen analysis, diagnostic accuracy, and clinical decision support while following global best practices.
Rigorous science, practical workflows, measurable impact.
Our approach starts with the needs of patients, clinicians, and laboratories, then works backward into product design.
Patient-centered
We focus on interventions that can improve survival, recovery, and quality of care.
Clinically grounded
Our solutions are shaped around real diagnostic constraints and existing care workflows.
Accessible by design
We aim for reliable, affordable tools that can work with standard clinical laboratory equipment.
Built for partnership
We collaborate with hospitals, laboratories, clinicians, researchers, and commercialization allies.
Our Pipeline
Indication
Feasibility
Prototype
Development
Regulatory Clearance
PathoVue
Pathogen DNA detection from whole blood samples (bacterial, viral, fungal)
N/A
PathoVue
Pathogen DNA detection from food and environmental samples (bacterial, viral, fungal)
N/A
SepSeek
Detection of specific pathogens and antimicrobial resistance genes associated with maternal and infant sepsis
SepSeek
Detection of more than 60 pathogens and antimicrobial resistance genes broadly associated with sepsis
SepSeek
Inflammation: host-response genes for early detection & guidance
ClinSight
Clinical Decision Support Assistant: EHR integrated, near real-time sepsis risk scoring and recommendations
N/A
Marks current development phase
Not applicable
OUR ROADMAP
Building a connected healthcare diagnostics enterprise.
Delphine's long-term direction extends from rapid assays and decision support into connected laboratory services and privacy-conscious health data analytics.
Advance rapid molecular testing
Develop SepSeek and RUO assays for pathogen identification, with planned expansion into resistance and additional microbial targets.
Embed clinical intelligence
Develop Clinsight as an explainable sepsis risk and decision-support experience designed for integration with hospital EHR systems.
Connect labs and health data
Establish broader testing and analytics services through certified laboratory networks and secure, regulation- aligned health data infrastructure.
We envision a future where every treatable infection is swiftly identified, precisely managed, and never allowed to claim a life — a world where preventable deaths from infection are eliminated.
Our mission is to transform infectious disease care by equipping clinicians with advanced diagnostics and machine‑learning insights that drive rapid, precise, and life-saving treatment decisions — beginning with sepsis.
The Core Team
Clinical Advisory Board
Advisors & Consultants
Industry Advisors
A strategic technology leader with expertise in building high-performance global teams, managing outcomes that improve customer centricity, and delivering large, complex projects.
Andy has added significant value to a major healthcare company and startup firms. He has held leadership positions in pharmaceutical, technology, and nonprofit organizations to lead strategic initiatives.
Education
- M.Tech, Computer Science and Engineering, Indian Institute of Technology Madras
- MBA, Technology Management, Stevens Institute of Technology
- BE (Honors), Electronics and Communication Engineering, PSG College of Technology
Ravindran Kumar is a highly accomplished life sciences professional with a Ph.D. in Life Science, a master's degree in Genetic Engineering, a bachelor's degree in Microbiology, and a diploma in Computational Biology.
With more than 15 years of hands-on experience in molecular diagnostics, he is recognized for expertise in microbiology, molecular biology, genetics, and molecular assay development.
Amy Flynn is the Founding Partner of CatMa Consulting, a firm focused on enabling leaders and organizations to drive growth and transformation. She brings extensive life sciences experience with deep expertise in operations, strategy, and organizational transformation.
She began her career across the product value chain with Johnson & Johnson, Pfizer, and Whatman Bioscience. She later held senior leadership roles at Grant Thornton, leading its Global Life Sciences Industry and National Life Sciences Operations Transformation Practice.
Amy is actively involved in mentoring and leadership development, including initiatives focused on women in business and leadership.
Qualifications
- Bachelor's degree in Engineering
- MBA, Rutgers University
- Master's in Education, Temple University
- Graduated cum laude from Rutgers University with a BA in Molecular Biology and Biochemistry.
- Experienced in molecular biology research, diagnostic assay development, human sample processing, DNA extraction, qPCR, and experimental data analysis.
- Contributed to Delphine's PCR-based sepsis detection assay through laboratory workflows, assay optimization, and research documentation.
- Conducted genetics, oncology, and neurobiology research resulting in a peer-reviewed publication and multiple research presentations.
Dr. Steven Simpson is certified by the American Board of Internal Medicine with subcertifications in pulmonary disease and critical care medicine. He completed a fellowship at Rush-Presbyterian St. Luke's Medical Center, earned his medical degree from the University of Kansas School of Medicine, and completed his residency at the University of Kansas Medical Center.
Himanshu Bhatia has more than twenty years of experience in the research, development, and commercialization of medical devices.
Education
- MBA, University of Rochester
- MS, Biochemistry, University of Texas Health Science Center
- MD, BJ Medical College
George is a professional bringing together his interests in medicine and business. Before pursuing his advanced studies, he served as a project manager in academia.
Education
- MD and MBA, Rutgers University
- BA, Johns Hopkins University
Dr. Nidhal Carla Bouaynaya is a Professor of Electrical and Computer Engineering and Director of the Machine & Artificial Intelligence and Virtual Reality Center at Rowan University. She leads research in AI and VR and helps guide Rowan University's institution-wide AI strategy, interdisciplinary collaboration, ethical AI adoption, and innovation.
She is the faculty lead for the NSF I-Corps Hub Northeast Region, Co-Founder and CTO of MRIMath LLC, and Founder of Deep AI Solutions, LLC. She advises Delphine Diagnostics on advanced AI technologies and precision healthcare solutions.
Dr. Ghulam Rasool works in the Department of Machine Learning at Moffitt Cancer Center, leading research at the intersection of AI and oncology. His work includes multimodal data integration, federated learning, and applying large language models to complex medical datasets.
He is a technical consultant to Delphine, collaborating on CDSA, the Clinical Decision Support Assistant machine learning product.
Raja Duraisamy is an accomplished technology leader specializing in IoT, data analytics, and telecommunications. He has built centers of excellence and led next-generation product development for global markets.
His experience includes commercializing remote plant-health monitoring for large farms across Asia, Europe, and North America, and delivering large telecommunications network rollouts in the APAC region.
Education
- ME, Computer Science, Indian Institute of Science, Bengaluru
Alfred W. D'Iorio has served as Executive Consultant and Chief Financial Officer for Delphine Diagnostics since November 2021. Previously, he held senior positions in public companies and private-equity portfolio companies across business services, retail, and drug manufacturing.
As CFO at MRI Network, he strengthened business planning, budgeting, financial analysis, legal management, and the information needed to prepare the company for sale. At Swiss Farms, he served as President, CEO, and CFO, building the infrastructure for regional growth and delivering strong gains in new-product sales and customer spending.
During 20 years with Johnson & Johnson's pharmaceutical division, Al served as Financial Manager, Tax Manager, Controller, and General Manager. He led complex pharmaceutical and medical-device manufacturing operations, facility expansion, new product introductions, capacity growth, and cost reduction.
Al holds a BS in Accounting from St. Joseph's University and is skilled in quality management systems and Six Sigma methodologies.
Todd Bailey is a technology R&D leader with deep experience building teams and developing solutions in advanced manufacturing, AI/ML, and complex systems engineering. He has led teams focused on data collection, model development and application, AI/ML, and MLOps.
His entrepreneurial background includes founding and contributing to early-stage real-estate investment and AI companies, with a focus on strategic planning, operational structure, and early execution.
Education
- Ph.D., Chemical Engineering, University of Texas at Austin
- SB, Chemical Engineering, Massachusetts Institute of Technology
- AS, Engineering Science, Hudson Valley Community College
Monica C. Smith is the CEO and founder of Marketsmith Inc., an award-winning performance marketing agency based in Whippany, New Jersey.
Over more than 25 years, Monica and Marketsmith have delivered results for brands including Shark/Ninja, Tumi, Bluemercury, and Lovesac. She has also helped drive creative and go-to-market design for major New Jersey behavioral-change campaigns including GetCoveredNJ, ReachNJ, and the 988 Suicide & Crisis Lifeline.
Her approach combines data and artificial intelligence with human insight, experience, and creativity to produce consumer-centered marketing and business results.
Monica holds a BA in Communication and Media Studies from the University of Mount Saint Vincent.
Raj Devalapalli is an experienced pharmaceutical professional, entrepreneur, and author. His education includes BS and MS degrees in Pharmacy, an MS in Industrial Pharmacy from Long Island University, and an MBA in Pharmaceutical Studies from Fairleigh Dickinson University. He is also a licensed pharmacist in New Jersey.
His career has included Lupin Labs, NutriPharm, TimeRx, Penwest, Becton Dickinson, Warner-Lambert, Pfizer, RiconPharma, Mirror, and Ingenus. His expertise spans product and process development, scale-up, technology transfer, manufacturing, validation, quality, regulatory affairs, and compliance.
Raj co-founded RiconPharma in 2008, helped acquire MirrorPharma in 2010, and participated in the 2014 merger with Ingenus Pharmaceuticals. The business expanded globally across New Jersey, Florida, Switzerland, and India.
Help bring faster, smarter infection diagnostics closer to patients.
We welcome conversations with hospitals, laboratories, clinicians, researchers, strategic partners, and healthcare organizations working to improve infectious disease outcomes.